DK3332789T3 - Cladribinkur til behandling af multipel sklerose - Google Patents
Cladribinkur til behandling af multipel sklerose Download PDFInfo
- Publication number
- DK3332789T3 DK3332789T3 DK18151634.5T DK18151634T DK3332789T3 DK 3332789 T3 DK3332789 T3 DK 3332789T3 DK 18151634 T DK18151634 T DK 18151634T DK 3332789 T3 DK3332789 T3 DK 3332789T3
- Authority
- DK
- Denmark
- Prior art keywords
- cladribincur
- treatment
- multiple sclerosis
- sclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63866904P | 2004-12-22 | 2004-12-22 | |
| EP04106909 | 2004-12-22 | ||
| EP14001970.4A EP2805723B1 (en) | 2004-12-22 | 2005-12-20 | Cladribine regimen for treating multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3332789T3 true DK3332789T3 (da) | 2022-07-11 |
Family
ID=36227798
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK22166610.0T DK4070800T3 (da) | 2004-12-22 | 2005-12-20 | Cladribinkur til behandling af multipel sklerose |
| DK14001970.4T DK2805723T3 (da) | 2004-12-22 | 2005-12-20 | Cladribin-regime til behandling af multipel sclerose |
| DK18151634.5T DK3332789T3 (da) | 2004-12-22 | 2005-12-20 | Cladribinkur til behandling af multipel sklerose |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK22166610.0T DK4070800T3 (da) | 2004-12-22 | 2005-12-20 | Cladribinkur til behandling af multipel sklerose |
| DK14001970.4T DK2805723T3 (da) | 2004-12-22 | 2005-12-20 | Cladribin-regime til behandling af multipel sclerose |
Country Status (25)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE059133T2 (hu) | 2004-12-22 | 2022-10-28 | Merck Serono Sa | Kladribin adagolási elõírás szklerózi multiplex kezelésére |
| MX2008014971A (es) | 2006-05-24 | 2008-12-05 | Serono Lab | Regimen de cladribine para tratar esclerosis multiple. |
| EP2343074A1 (en) | 2009-12-23 | 2011-07-13 | Merck Serono S.A. | Use of purine analogues for treating airway diseases |
| WO2011117267A1 (en) | 2010-03-24 | 2011-09-29 | Merck Serono Sa | Cladribine treatment of multiple sclerosis in patient groups defined by genotype |
| EP2428201A1 (en) | 2010-09-08 | 2012-03-14 | Merck Serono S.A. | Oral administration of nucleoside monophosphates |
| WO2012097867A1 (en) | 2011-01-18 | 2012-07-26 | Synthon Bv | Cladribine particles and pharmaceutical compositions comprising them |
| GB201401465D0 (en) | 2014-01-29 | 2014-03-12 | Roach Arthur H | Use of cladribine for treating autoimmune inflammatory disease |
| GB2564717A (en) * | 2017-07-21 | 2019-01-23 | Chord Therapeutics S A R L | Use of cladribine for treating autoimmune neuromuscular disease |
| TWI869330B (zh) * | 2017-11-24 | 2025-01-11 | 德商馬克專利公司 | 用於治療進展型多發性硬化症之克拉屈濱(cladribine)療程 |
| GB2601786A (en) * | 2020-12-10 | 2022-06-15 | Chord Therapeutics S A R L | Use of cladribine for treating immune brain disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1269659A (en) | 1984-08-06 | 1990-05-29 | Brigham Young University | Method for the production of 2'-deoxyadenosine compounds |
| US5310732A (en) | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US4964848A (en) * | 1988-06-27 | 1990-10-23 | Bloom Philip M | Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression |
| US5208327A (en) | 1991-12-18 | 1993-05-04 | Ortho Pharmaceutical Corporation | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine |
| US5641757A (en) | 1994-12-21 | 1997-06-24 | Ortho Pharmaceutical Corporation | Stable 2-chloro-2'-deoxyadenosine formulations |
| HUT77928A (hu) | 1994-12-22 | 1998-11-30 | Ortho Pharmaceutical Corporation | Oldható 2-klór-2'-dezoxi-adenozint tartalmazó gyógyászati készítmények |
| US6194395B1 (en) | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
| WO2000064918A1 (en) | 1999-04-28 | 2000-11-02 | Sterrenbeld Biotechnologie North America, Inc. | METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE |
| DE10237146A1 (de) * | 2002-08-13 | 2004-03-04 | Medac Gesellschaft für klinische Spezialpräparate mbH | Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose |
| JP4757632B2 (ja) | 2002-09-25 | 2011-08-24 | ブリガム ヤング ユニバーシティー | ２’−デオキシグアノシンから２−クロロ−２’−デオキシアデノシンを調製する方法 |
| GB2394658A (en) * | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| BRPI0407781A (pt) * | 2003-02-25 | 2006-02-14 | Applied Research Systems | aplicação combinada de ribavirina e interferon beta em doenças desmielinizantes |
| US20070065492A1 (en) | 2003-03-28 | 2007-03-22 | Ivax Corporation | Cladribine formulations for improved oral and transmucosal delivery |
| KR101129816B1 (ko) | 2003-03-28 | 2012-03-26 | 아레스 트레이딩 에스.아. | 클라드리빈의 경구용 제형 |
| HUE059133T2 (hu) | 2004-12-22 | 2022-10-28 | Merck Serono Sa | Kladribin adagolási elõírás szklerózi multiplex kezelésére |
| MX2008014971A (es) * | 2006-05-24 | 2008-12-05 | Serono Lab | Regimen de cladribine para tratar esclerosis multiple. |
-
2005
- 2005-12-20 HU HUE18151634A patent/HUE059133T2/hu unknown
- 2005-12-20 HR HR20120228T patent/HRP20120228T1/hr unknown
- 2005-12-20 EP EP24206496.2A patent/EP4523753A3/en active Pending
- 2005-12-20 EA EA200701221A patent/EA015799B1/ru active Protection Beyond IP Right Term
- 2005-12-20 ES ES22166610T patent/ES3007339T3/es active Active
- 2005-12-20 MX MX2007007610A patent/MX2007007610A/es unknown
- 2005-12-20 EP EP05823474A patent/EP1827461B1/en active Active
- 2005-12-20 LT LTEP18151634.5T patent/LT3332789T/lt unknown
- 2005-12-20 LT LTEP22166610.0T patent/LT4070800T/lt unknown
- 2005-12-20 DK DK22166610.0T patent/DK4070800T3/da active
- 2005-12-20 KR KR1020077016508A patent/KR20070091662A/ko not_active Ceased
- 2005-12-20 SG SG201001736-6A patent/SG160391A1/en unknown
- 2005-12-20 CA CA2588966A patent/CA2588966C/en active Active
- 2005-12-20 AU AU2005318190A patent/AU2005318190B2/en active Active
- 2005-12-20 PL PL18151634.5T patent/PL3332789T3/pl unknown
- 2005-12-20 PL PL22166610.0T patent/PL4070800T3/pl unknown
- 2005-12-20 PL PL14001970T patent/PL2805723T3/pl unknown
- 2005-12-20 SI SI200532305T patent/SI3332789T1/sl unknown
- 2005-12-20 EP EP18151634.5A patent/EP3332789B1/en active Active
- 2005-12-20 US US11/722,018 patent/US7713947B2/en active Active
- 2005-12-20 HU HUE22166610A patent/HUE070333T2/hu unknown
- 2005-12-20 PL PL05823474T patent/PL1827461T3/pl unknown
- 2005-12-20 JP JP2007547486A patent/JP5795456B2/ja active Active
- 2005-12-20 FI FIEP22166610.0T patent/FI4070800T3/fi active
- 2005-12-20 DK DK14001970.4T patent/DK2805723T3/da active
- 2005-12-20 CA CA3087419A patent/CA3087419C/en active Active
- 2005-12-20 WO PCT/EP2005/056954 patent/WO2006067141A1/en active Application Filing
- 2005-12-20 BR BRPI0517132A patent/BRPI0517132B8/pt active IP Right Grant
- 2005-12-20 EP EP10182676.6A patent/EP2263678B1/en active Active
- 2005-12-20 EP EP10182632.9A patent/EP2275110B1/en active Active
- 2005-12-20 EP EP22166610.0A patent/EP4070800B1/en active Active
- 2005-12-20 EP EP14001970.4A patent/EP2805723B1/en not_active Revoked
- 2005-12-20 SI SI200532191T patent/SI2805723T1/en unknown
- 2005-12-20 SI SI200532321T patent/SI4070800T1/sl unknown
- 2005-12-20 ES ES18151634T patent/ES2921858T3/es active Active
- 2005-12-20 DK DK18151634.5T patent/DK3332789T3/da active
- 2005-12-21 AR ARP050105411A patent/AR052830A1/es not_active Application Discontinuation
-
2007
- 2007-06-14 IL IL183930A patent/IL183930A0/en active IP Right Grant
- 2007-07-20 NO NO20073813A patent/NO20073813L/no not_active Application Discontinuation
-
2010
- 2010-04-23 US US12/766,173 patent/US8377903B2/en active Active
-
2011
- 2011-02-23 AU AU2011200768A patent/AU2011200768B2/en active Active
- 2011-04-17 IL IL212421A patent/IL212421A/en active IP Right Grant
-
2012
- 2012-04-11 CY CY20121100358T patent/CY1112614T1/el unknown
-
2013
- 2013-05-30 JP JP2013113850A patent/JP5908863B2/ja active Active
-
2015
- 2015-06-16 JP JP2015120875A patent/JP6092945B2/ja active Active
-
2016
- 2016-04-08 JP JP2016078293A patent/JP6290962B2/ja active Active
-
2017
- 2017-02-09 JP JP2017022375A patent/JP6430554B2/ja active Active
-
2018
- 2018-01-18 CY CY20181100065T patent/CY1119790T1/el unknown
- 2018-02-12 LU LU00064C patent/LUC00064I2/fr unknown
- 2018-02-14 FR FR18C1008C patent/FR18C1008I2/fr active Active
- 2018-02-15 HU HUS1800009C patent/HUS1800009I1/hu unknown
- 2018-02-20 LT LTPA2018503C patent/LTC2805723I2/lt unknown
- 2018-02-28 CY CY2018006C patent/CY2018006I1/el unknown
- 2018-07-09 JP JP2018129918A patent/JP2018165271A/ja active Pending
-
2020
- 2020-08-06 JP JP2020134010A patent/JP2020193206A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1828164T3 (da) | Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider | |
| DK1778668T3 (da) | Fremgangsmåde til fremstilling af dihydropteridion | |
| DK3403657T3 (da) | Anvendelse af oligouronater til behandling af slimhyperviskositet | |
| DK1701941T3 (da) | Forbindelser til behandling af sygdomme med celleproliferation | |
| DK1720571T3 (da) | Fremgangsmåde til behandling af hæmolytisk sygdom | |
| DK1928438T3 (da) | Anvendelse af ibudilast til behandling af stofafhængighed | |
| DK2137537T3 (da) | Sammensætninger og anvendelser til behandling af multipel sklerose | |
| DK2308507T3 (da) | Fremgangsmåder til behandling af præeklampsi | |
| DK1893586T3 (da) | Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler | |
| DK1720866T3 (da) | Fremgangsmåde | |
| DK1755661T3 (da) | Gelsolin til anvendelse til behandling af infektioner | |
| DK1567152T3 (da) | Anvendelse af rasagilin med riluzol til behandling af amyotroph lateral sklerose | |
| DK1708992T3 (da) | Sulfonamidderivater til behandling af sygdomme | |
| DK1801108T3 (da) | Morpholinforbindelser til behandling af inflammationer. | |
| DK3332789T3 (da) | Cladribinkur til behandling af multipel sklerose | |
| DK1763520T3 (da) | Anvendelse af trisubstituerede benzopyranoner | |
| DK1687297T3 (da) | Triazindimerer til behandling af autoimmunsygdomme | |
| DK1709082T3 (da) | Sammensætning til behandling af patologi knyttet til MSRV/HERV-W | |
| DK1541137T3 (da) | Transdermalt delivery system af gestoden | |
| DK1912961T3 (da) | Fremgangsmåde til fremstilling af bepromolin | |
| DK1831223T3 (da) | Fremgangsmåde til fremstilling af L-biopterin | |
| DK1940447T3 (da) | Behandling af neurodegenrative lidelser | |
| DK1814555T3 (da) | S-mirtazapin til behandling af hedeture | |
| DK1789529T3 (da) | Fremgangsmåde til forbedring af konserveringen af lactococcus | |
| DK1812002T3 (da) | Behandling af mastitis |